Zoetis Inc (NYSE:ZTS) insider Roman Trawicki sold 23,885 shares of Zoetis stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $82.00, for a total transaction of $1,958,570.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of Zoetis Inc (NYSE ZTS) traded up $2.03 on Friday, hitting $82.79. 2,697,182 shares of the company’s stock were exchanged, compared to its average volume of 3,080,078. Zoetis Inc has a 1-year low of $52.25 and a 1-year high of $82.93. The firm has a market capitalization of $39,980.00, a PE ratio of 37.98, a PEG ratio of 1.81 and a beta of 1.07. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 15th. The company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.03. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same period last year, the business earned $0.47 earnings per share. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. equities analysts forecast that Zoetis Inc will post 3.03 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be given a dividend of $0.126 per share. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s dividend payout ratio is presently 22.94%.
A number of equities analysts have commented on the stock. Deutsche Bank lifted their target price on shares of Zoetis from $76.00 to $78.00 and gave the stock a “hold” rating in a research note on Friday, February 16th. Barclays set a $77.00 target price on shares of Zoetis and gave the stock a “hold” rating in a research note on Saturday, February 17th. Piper Jaffray Companies set a $88.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research note on Friday, February 16th. Cowen set a $85.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research note on Thursday, February 15th. Finally, Cantor Fitzgerald set a $90.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research note on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $79.83.
Institutional investors and hedge funds have recently made changes to their positions in the business. Chemical Bank acquired a new position in shares of Zoetis in the fourth quarter valued at approximately $350,000. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Zoetis by 27.9% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 17,881 shares of the company’s stock valued at $1,288,000 after purchasing an additional 3,904 shares in the last quarter. Xact Kapitalforvaltning AB grew its holdings in shares of Zoetis by 9.8% in the fourth quarter. Xact Kapitalforvaltning AB now owns 70,114 shares of the company’s stock valued at $5,051,000 after purchasing an additional 6,253 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of Zoetis by 31.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 134,904 shares of the company’s stock valued at $9,719,000 after purchasing an additional 32,149 shares in the last quarter. Finally, Dixon Hubard Feinour & Brown Inc. VA grew its holdings in shares of Zoetis by 106.2% in the fourth quarter. Dixon Hubard Feinour & Brown Inc. VA now owns 25,090 shares of the company’s stock valued at $1,807,000 after purchasing an additional 12,925 shares in the last quarter. Institutional investors and hedge funds own 94.18% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Zoetis Inc (ZTS) Insider Sells $1,958,570.00 in Stock” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/23/zoetis-inc-zts-insider-sells-1958570-00-in-stock.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.